Literature DB >> 1752785

Antitumor effector mechanism of interleukin-1 beta at a distant site in the double grafted tumor system.

T Ebina1, K Murata.   

Abstract

Recombinant human interleukin-1 beta (IL-1 beta) inhibited the growth of not only the right, but also the left non-treated tumor in a double grafted tumor system. Since the antitumor activity of IL-1 beta against the right and left tumors was not seen in nude mice, lymphocytes have a key role in the antitumor effect of intratumoral administration of IL-1 beta. TIL (tumor-infiltrating leukocytes) obtained from left and right side tumors treated with IL-1 beta were examined by Winn assay for their antitumor activity against Meth-A sarcoma in BALB/c mice. TIL from the right side clearly inhibited the growth of admixed Meth-A cells, but control TIL did not. Spleen cells and right and left regional lymph node cells prepared from IL-1-treated mice were examined for Lyt-1, Lyt-2 and L3T4 phenotypes. The number of Lyt-1-positive lymphocytes increased in the spleen and in the right regional lymph nodes after intratumoral administration of IL-1. Isolated tumor cells obtained from the right tumor treated with IL-1 beta and the left side tumor on day 6 were cultured in RPMI 1640 with 10% fetal calf serum for 24 h. The culture supernatants were harvested and tested for the presence of chemotactic activity for neutrophils or macrophages. Significant neutrophil chemotactic factor and macrophage chemotactic factor activities were detected in the culture media from IL-1-treated tumor tissues cultured for 24 h. Neither significant neutrophil nor macrophage chemotactic activity was detected in the media from untreated tumor tissues. These results suggest that intratumoral administration of IL-1 first induces neutrophils and macrophages in the right tumor, then Lyt-1-positive cells in the right regional lymph nodes and in the spleen, and subsequently induces macrophages in the left, non-treated tumor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1752785      PMCID: PMC5918313          DOI: 10.1111/j.1349-7006.1991.tb01795.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


interleukin‐1 inter‐leukin‐8 monocyte chemotactic and activating factor tumor‐infiltrating leukocytes peritoneal exudate cells fluorescence‐activated cell sorter phosphate‐buffered saline fetal calf serum neutrophil chemotactic factor
  22 in total

1.  Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts.

Authors:  H J WINN
Journal:  J Immunol       Date:  1961-02       Impact factor: 5.422

2.  Site-specific mutagenesis of the human interleukin-1 beta gene: structure-function analysis of the cysteine residues.

Authors:  T Kamogashira; Y Masui; Y Ohmoto; T Hirato; K Nagamura; K Mizuno; Y M Hong; Y Kikumoto; S Nakai; Y Hirai
Journal:  Biochem Biophys Res Commun       Date:  1988-02-15       Impact factor: 3.575

3.  Production of interleukin-8 by human dermal fibroblasts and keratinocytes in response to interleukin-1 or tumour necrosis factor.

Authors:  C G Larsen; A O Anderson; J J Oppenheim; K Matsushima
Journal:  Immunology       Date:  1989-09       Impact factor: 7.397

4.  Cytokine-induced gene expression of a neutrophil chemotactic factor/IL-8 in human hepatocytes.

Authors:  A J Thornton; R M Strieter; I Lindley; M Baggiolini; S L Kunkel
Journal:  J Immunol       Date:  1990-04-01       Impact factor: 5.422

5.  Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor.

Authors:  A Sica; J M Wang; F Colotta; E Dejana; A Mantovani; J J Oppenheim; C G Larsen; C O Zachariae; K Matsushima
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

6.  Chemotactic factor and P15E-related chemotaxis inhibitor in human melanoma cell lines with different macrophage content and tumorigenicity in nude mice.

Authors:  A Benomar; W J Ming; G Taraboletti; P Ghezzi; C Balotta; G J Cianciolo; R Snyderman; J F Doré; A Mantovani
Journal:  J Immunol       Date:  1987-04-01       Impact factor: 5.422

7.  Phenotype of cytotoxic effector cells infiltrating a transplanted, chemically induced rat sarcoma.

Authors:  B L Ferry; G R Flannery; R A Robins; J Lawry; R W Baldwin
Journal:  Immunology       Date:  1984-10       Impact factor: 7.397

8.  Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line.

Authors:  C O Zachariae; A O Anderson; H L Thompson; E Appella; A Mantovani; J J Oppenheim; K Matsushima
Journal:  J Exp Med       Date:  1990-06-01       Impact factor: 14.307

9.  Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line.

Authors:  K Matsushima; C G Larsen; G C DuBois; J J Oppenheim
Journal:  J Exp Med       Date:  1989-04-01       Impact factor: 14.307

10.  Antitumor effect of interleukin-1 beta in the double grafted tumor system.

Authors:  T Ebina; K Ishikawa
Journal:  Jpn J Cancer Res       Date:  1989-06
View more
  4 in total

1.  Prevention of lymph node metastases by adoptive transfer of CD4+ T lymphocytes admixed with irradiated tumor cells.

Authors:  K Yoshida; T Tachibana
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

2.  Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 beta.

Authors:  G R Peplinski; K Tsung; E D Whitman; J B Meko; J A Norton
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

3.  Antitumor effect of PSK at a distant site: tumor-specific immunity and combination with other chemotherapeutic agents.

Authors:  T Ebina; K Murata
Journal:  Jpn J Cancer Res       Date:  1992-07

4.  Antitumor effect of intratumoral administration of biological response modifiers: induction of immunosuppressive acidic protein, a type of alpha 1-acid glycoprotein, in mice.

Authors:  T Ebina; K Murata; K Tamura
Journal:  Jpn J Cancer Res       Date:  1994-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.